Table 3.
Prostate Biopsy Nomograms for Prediction of Prostate Cancer Presence in Initial Biopsy Setting
Reference | Prediction Form | Number of Patients | Variables | Mean Number of Cores (Range) | Cancer Detection Rate (%) | Accuracy (%) | Validation |
Babaian RJ et al.131 | Risk group | 151 | Age, creatinine phosphokinase isoenzyme activity, prostatic acid phosphatase, PSA | 6 | 24 | 74 | Not performed |
Eastham JA et al110 | Probability nomogram development | 700 | Age, race, DRE, PSA (0–4 ng/mL) | 6 | 9 | 75 | Internal |
Virtanen A et al132 | Neural network | 212 | Percentage free PSA, DRE, heredity | Not available | 25 | 81 | Not performed |
Finne P et al133 | Neural network | 656 | Percentage free PSA, PSA, DRE, TRUS | Not available | 23 | Not available | Not performed |
Horninger W et al134 | Neural network | 3474 | Age, PSA, percentage free PSA, DRE, TRUS, PSA density, PSA density of transition zone, transition zone volume | Not available | Not available | Not available | Not performed |
Kalra P et al135 | Neural network | 348 | Age, ethnicity, heredity, IPSS, DRE, PSA, complexed PSA | 6 | Not available | 83 | Not performed |
Garzotto M et al111 | Probability nomogram development | 1239 | Age, race, family history, referral indications, prior vasectomy, DRE, PSA (≤ 10 ng/mL), PSA density, TRUS findings | 6.7 (6–13) | 24 | 73 | Not performed |
Finne P et al136 | Neural network | 1775 | DRE, percentage free PSA, TRUS, PSA | Not available | 22 | 76 | Not performed |
Karakiewicz PI et al112 | Probability nomogram development | 6469 | Age, DRE, PSA, percentage free PSA | 6 | 35–42 | 77 | Internal and external |
Suzuki H et al137 | Probability nomogram development | 834 | Age, PSA, percentage free PSA, prostate volume, DRE | ≥ 6 | 29 | 82 | Internal |
Chun FK et al128 | Probability nomogram validation112 and development | 2900 | Age, DRE, PSA, percentage free PSA, sampling density* | 11 (10–20) | 41 | 77 | Internal and external |
Porter CR et al138 | Neural network | 3814 | Age, PSA, gland volume, PSA density, DRE, TRUS | 6 | 27–42 | 72–75 | Internal and external |
Sampling density = ratio of TRUS-derived total gland volume by the number of cores at biopsy.
DRE, digital rectal examination; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen; TRUS, transrectal ultrasound of the prostate.